Globus Medical Stock Soars 19.2% After Strong Q3 Results
Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q3 CY2025, with sales up 22.9% year on year to $769 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $1.18 per share was 53.4% above analysts’ consensus estimates.
Globus Medical’s Q3 CY2025 highlights included revenue of $769 million, representing a 22.9% year-over-year increase, exceeding analyst estimates by 4.7%. Adjusted earnings per share (EPS) reached $1.18, a 53.4% beat against consensus forecasts. The company also raised its full-year revenue guidance to $2.88 billion at the midpoint and increased its full-year Adjusted EPS guidance to $3.80 at the midpoint, reflecting a 20.6% increase. Operating Margin reached 17.9%, up significantly from 7.7% in the same quarter last year, alongside a Free Cash Flow Margin of 27.8%, up from 25.8% in the same period. The company’s annualized revenue growth over the last five years has been a strong 29.3%, outpacing the average growth of the broader healthcare sector.
Globus Medical, operating in 64 countries with a substantial portfolio of over 10 new products launched in 2023, develops and sells implantable devices, surgical instruments, and technology solutions focused on spine, orthopedic, and neurosurgical procedures. The firm’s financial performance demonstrated operational efficiencies and strategic growth initiatives. The company’s President and Chief Executive Officer, Keith Pfeil, noted that the company’s results were "pleasing" and underscored continued progress.
Over the past five years, Globus Medical has maintained an average operating margin of 12.7%, a commendable figure compared to the broader healthcare sector. However, this margin has decreased by 9.2 percentage points over the same timeframe, indicating rising expenses that were not fully passed on to customers. Additionally, the company’s diluted shares outstanding increased by 34.7% over the same period, which suggests that the firm has become less profitable on a per-share basis as it expanded operations. Its EPS grew at an astounding 21.6% compounded annual growth rate over the last five years, though this lagged behind its 29.3% annualized revenue growth.
Looking ahead, sell-side analysts project revenue growth of 9.7% over the next 12 months, signaling a slight deceleration from the previous two years. Despite this slowdown, the market’s continued confidence is evidenced by the raised full-year guidance and projected EPS.
